Suppr超能文献

开发的纳米免疫协同剂增强小胶质细胞功能,改善恶性脑胶质瘤治疗中的免疫缺陷。

Enhancement of Microglia Functions by Developed Nano-Immuno-Synergist to Ameliorate Immunodeficiency for Malignant Glioma Treatment.

机构信息

Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai, 201203, P. R. China.

Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, 201203, P. R. China.

出版信息

Adv Healthc Mater. 2023 Dec;12(30):e2301861. doi: 10.1002/adhm.202301861. Epub 2023 Sep 12.

Abstract

Resident microglia are key factors in mediating immunity against brain tumors, but the microglia in malignant glioma are functionally impaired. Little immunotherapy is explored to restore microglial function against glioma. Herein, oleanolic acid (OA) (microglia "restorer") and PPA-1 peptide (immune checkpoint blockade) are integrated on a nano-immuno-synergist ( PAM@OA) to work coordinately. The self-assembled OA core is coated with macrophage membrane for efficient blood-brain barrier penetration and microglia targeting, on which PPA-1 peptide is attached via acid-sensitive bonds for specific release in tumor microenvironment. With the enhanced accumulation of the dual drugs in their respective action sites, PAM@OA effectively promotes the recruitment and activation of effector T cells by inhibiting aberrant activation of Signal transducer and activator of transcription (STAT-3) pathway in microglia, and assists activated effector T cells in killing tumor cells by blocking elevated immune checkpoint proteins in malignant glioma. Eventually, as adjuvant therapy, the rationally designed nano-immuno-synergist hinders malignant glioma progression and recurrence with or without temozolomide. The work demonstrates the feasibility of a nano-formulation for microglia-based immunotherapy, which may provide a new direction for the treatment of brain tumors.

摘要

脑肿瘤中,驻留小胶质细胞是介导抗肿瘤免疫的关键因素,但恶性神经胶质瘤中的小胶质细胞功能受损。目前很少有免疫疗法来恢复针对神经胶质瘤的小胶质细胞功能。在此,齐墩果酸(OA)(小胶质细胞“修复剂”)和 PPA-1 肽(免疫检查点阻断剂)被整合到纳米免疫协同剂(PAM@OA)上,以协同作用。自组装的 OA 核心被巨噬细胞膜包覆,以实现高效的血脑屏障穿透和小胶质细胞靶向,其上通过酸敏感键连接 PPA-1 肽,以便在肿瘤微环境中特异性释放。通过在各自作用部位增强两种药物的积累,PAM@OA 通过抑制小胶质细胞中信号转导和转录激活因子(STAT-3)途径的异常激活,有效促进效应 T 细胞的募集和激活,并通过阻断恶性神经胶质瘤中升高的免疫检查点蛋白,协助激活的效应 T 细胞杀死肿瘤细胞。最终,作为辅助治疗,这种合理设计的纳米免疫协同剂可阻止恶性神经胶质瘤的进展和复发,无论是否使用替莫唑胺。该工作展示了基于小胶质细胞的免疫疗法的纳米制剂的可行性,为脑肿瘤的治疗提供了新的方向。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验